From Wikipedia, the free encyclopedia
Chemical compound
Tedalinab
|
|
(4S,7R)-1-(2,4-difluorophenyl)-N-(1,1-dimethylethyl)-4,5,6,7-tetrahydro-4,7-methano-1H-indazole-3-carboxamide
|
CAS Number | |
---|
PubChem
CID | |
---|
ChemSpider | |
---|
UNII | |
---|
|
Formula | C19H21F2N3O |
---|
Molar mass | 345.394 g·mol−1 |
---|
3D model (
JSmol) | |
---|
CC(C)(C)NC(=O)C1=NN(C2=C1[C@@H]3CC[C@H]2C3)C4=C(C=C(C=C4)F)F
|
InChI=1S/C19H21F2N3O/c1-19(2,3)22-18(25)16-15-10-4-5-11(8-10)17(15)24(23-16)14-7-6-12(20)9-13(14)21/h6-7,9-11H,4-5,8H2,1-3H3,(H,22,25)/t10-,11+/m0/s1 Key:NTPZXHMTJGOMCJ-WDEREUQCSA-N
|
Tedalinab (GRC-10693) is a drug developed by
Glenmark Pharmaceuticals for the treatment of
osteoarthritis and
neuropathic pain, which acts as a potent and selective
cannabinoid
CB2
receptor
agonist. It has a very high selectivity of 4700x for CB2 over the related
CB1 receptor, has good oral bioavailability and has shown promising safety results and effective
analgesic and
antiinflammatory actions in early
clinical trials.
[1] Many related compounds are known, most of which also show high CB2 selectivity.
[2]
See also
References
|
---|
Phytocannabinoids (
comparison) | Cannabibutols | |
---|
Cannabichromenes | |
---|
Cannabicyclols | |
---|
Cannabidiols | |
---|
Cannabielsoins | |
---|
Cannabigerols | |
---|
Cannabiphorols | |
---|
Cannabinols | |
---|
Cannabitriols | |
---|
Cannabivarins | |
---|
Delta-8-tetrahydrocannabinols | |
---|
Delta-9-tetrahydrocannabinols | |
---|
Delta-10-Tetrahydrocannabinols | |
---|
Miscellaneous cannabinoids | |
---|
Active metabolites | |
---|
|
---|
Endocannabinoids | |
---|
Synthetic cannabinoid receptor agonists / neocannabinoids | Classical cannabinoids (dibenzopyrans) | |
---|
Non-classical cannabinoids | |
---|
Adamantoylindoles | |
---|
Benzimidazoles | |
---|
Benzoylindoles | |
---|
Cyclohexylphenols | |
---|
Eicosanoids | |
---|
Hydrocarbons | |
---|
Indazole carboxamides | |
---|
Indazole-3- carboxamides | |
---|
Indole-3-carboxamides | |
---|
Indole-3-carboxylates | |
---|
Naphthoylindazoles | |
---|
Naphthoylindoles | |
---|
Naphthoylpyrroles | |
---|
Naphthylmethylindenes | |
---|
Naphthylmethylindoles | |
---|
Phenylacetylindoles | |
---|
Pyrazolecarboxamides | |
---|
Pyrrolobenzoxazines | |
---|
Quinolinyl esters | |
---|
Tetramethylcyclo- propanoylindazoles | |
---|
Tetramethylcyclo- propanoylindoles | |
---|
Tetramethylcyclo- propylindoles | |
---|
Others | |
---|
|
---|
Allosteric
CBRTooltip Cannabinoid receptor
ligands | |
---|
Endocannabinoid enhancers (inactivation inhibitors) | |
---|
Anticannabinoids (antagonists/inverse agonists/antibodies) | |
---|
|
|
---|
Receptor (
ligands) |
CB1Tooltip Cannabinoid receptor type 1 | Agonists (abridged,
full list) | |
---|
Inverse agonists | |
---|
Antagonists | |
---|
|
---|
CB2Tooltip Cannabinoid receptor type 2 | Agonists |
-
2-AG
-
2-AGE (noladin ether)
-
3,3'-Diindolylmethane
-
4-O-Methylhonokiol
-
α-Amyrin · β-Amyrin
-
A-796,260
-
A-834,735
-
A-836,339
-
AM-1172
-
AM-1221
-
AM-1235
-
AM-1241
-
AM-2232
-
Anandamide
-
AZ-11713908
-
Cannabinol
-
Caryophyllene
-
CB-13
-
CBS-0550
-
CP 55,940
-
GW-405,833 (L-768,242)
-
GW-842,166X
-
HU-308
-
JTE 7-31
-
JWH-007
-
JWH-015
-
JWH-018
-
JWH-73
-
JWH-133
-
L-759,633
-
L-759,656
-
Lenabasum (anabasum)
-
Magnolol
-
MDA-19
-
Nabitan
-
NADA
-
Olorinab (APD-371)
-
PF-03550096
-
S-444,823
-
SER-601
-
Serinolamide A
-
UR-144
-
Tedalinab
-
THC (dronabinol)
-
THCV
-
Tetrahydromagnolol
-
Virodhamine
|
---|
Antagonists | |
---|
|
---|
NAGly (
GPR18) | |
---|
GPR55 | |
---|
GPR119 | |
---|
|
---|
Transporter (
modulators) |
eCBTsTooltip Endocannabinoid transporter | |
---|
|
---|
Enzyme (
modulators) | |
---|
Others |
- Others:
2-PG (directly potentiates activity of 2-AG at CB1 receptor)
-
ARN-272 (FAAH-like anandamide transporter inhibitor)
|
---|
|